Abstract
Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Current Drug Targets
Title:Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives
Volume: 19 Issue: 11
Author(s): Daisuke Akagi*, Katsuyuki Hoshina, Toshiaki Watanabe and Micheal S. Conte
Affiliation:
- Division of Vascular and Endovascular Surgery, Department of Surgery, Cardiovascular Research Institute, University of California, San Francisco CA 94117,United States
Keywords: Abdominal aortic aneurysm (AAA), drug therapy, inflammation, omega-3 polyunsaturated fatty acid (PUFA), resolvin, intraluminal thrombus.
Abstract: Background: Abdominal aortic aneurysms (AAA) are life-threatening because of the potential for rupture, resulting in death. The current standard treatment for AAA is surgery, comprising laparotomic graft replacement and endovascular repair. However, because surgery carries the risk of major complications and re-intervention, drug therapies are desirable because they may reduce the occurrence of enlargement and rupture.
Objective: Recent research shows that the progression of AAA is related to inflammatory reactions, especially those in the NF-κB pathway. Omega-3 polyunsaturated fatty acids (PUFA) show antiinflammatory effects. Some derivatives of omega-3 PUFA are known as specialized pro-resolving lipid mediators (SPM) such as resolvins. They play an important role in resolving inflammation.
Conclusion: Omega-3 PUFA and SPM may show promised effects for drug treatment of AAA.
Export Options
About this article
Cite this article as:
Akagi Daisuke *, Hoshina Katsuyuki , Watanabe Toshiaki and Conte S. Micheal, Drug Therapy for Abdominal Aortic Aneurysms Utilizing Omega-3 Unsaturated Fatty Acids and Their Derivatives, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450118666171013101815
DOI https://dx.doi.org/10.2174/1389450118666171013101815 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Quantification of Shear Stress and Geometric Risk Factors in Carotid Atherosclerosis: Review and Clinical Evidence
Recent Patents on Medical Imaging Patent Selections
Recent Patents on DNA & Gene Sequences Inflammation and Immunology of the Vitreoretinal Compartment
Inflammation & Allergy - Drug Targets (Discontinued) Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures
Current Drug Targets Neuroinflammation is Associated with Brain Extracellular TAU-Protein Release After Spontaneous Subarachnoid Hemorrhage
Current Drug Targets Importance of Receptor-targeted Systems in the Battle Against Atherosclerosis
Current Pharmaceutical Design Novel Concept in the Mechanism of Injury and Protection of Gastric Mucosa: Role of Renin-Angiotensin System and Active Metabolites of Angiotensin
Current Medicinal Chemistry Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Meet Our Editorial Board Member
Current Medical Imaging Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Vascular Endothelial Primary Cilia: Mechanosensation and Hypertension
Current Hypertension Reviews The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Recent Patents on Biomedical Devices and Nanomaterials for Hyperthermal Therapy of Cancer
Recent Patents on Nanomedicine Distribution of Left Ventricular Thrombus among Patients with Significantly Impaired Systolic Function
New Emirates Medical Journal The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Patent Foramen Ovale in Cerebral Infarction
Current Cardiology Reviews Amino Acid Metabolic Routes in Trypanosoma cruzi: Possible Therapeutic Targets Against Chagas; Disease
Current Drug Targets - Infectious Disorders Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology